ArticleEnvironmental science and pollution research international2023
What is the optimal country for minimum COVID-19 morbidity and mortality rates?
Article in Environmental science and pollution research international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-healthcare system interventions and COVID-19 daily cases: a multilevel time series analysis.BMC public health · 2025Article
- Global trends in COVID-19 incidence and case fatality rates (2019-2023): a retrospective analysis.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 is a deceptive virus. Despite the remarkable progress in genetic sequencing and subsequent vaccine development, the world continues to grapple with the ominous threats of rapidly appearing SARS-CoV-2 variants. The objective of this manuscript is to rank world countries based on the anticipated scope of COVID-19 morbidity and mortality, measured in terms of prevalence per 1 million persons, from the lowest to the highest. The ranking of 162 countries is based on predictions of empirical models, which include three explanatory variables: hospital beds per thousand persons, population density, and the median age of the country's population. Referring to the COVID-19 scope of morbidity, the lowest likelihood of infection is obtained in Niger and Mali, where the dominant characteristic is the young median age (15.1-16.4 years). Referring to the COVID-19 scope of mortality, the lowest likelihood is obtained in Singapore. For Singapore, the dominant feature is the high population density. The optimal solution is intensive vaccination campaigns in the initial phase of the pandemic, particularly among countries with low GDP per capita. Yet, vaccinations may work only where the personal immune system is healthy and thus respond by creating antibodies to the SARS-CoV2 virus. Referring to populations that lack the natural protection of the healthy immune system and thus cannot be vaccinated (e.g., old people, cancer patients undergoing chemotherapy treatments), a complementary solution might be coordination between countries and the establishment of field hospitals, testing laboratories, isolation of areas, humanitarian aid-in the same manner of treatment in other disasters like earthquakes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.